Refeyn

Refeyn Ltd. specializes in the development, production, and distribution of mass photometry technologies for industry and academia. Mass photometry and macro mass photometry are unique bioanalytical technologies pioneered by Refeyn. By quantifying light scattering from particles in solution, mass photometry enables the measurement of molecular mass at the single-particle level while macro mass photometry enables simultaneous measurement of viral vector size and contrast (a proxy for mass). 

Spun out of Oxford University in 2018, the company aims to make its technology accessible to all in the scientific community, enabling users to achieve new and better outcomes. Refeyn has been recognized for its unique approach to biomolecular analysis through multiple awards, including the Royal Society of Chemistry Emerging Technologies Competition. Applications of mass photometry include: Characterization of samples of biomolecules and viral vectors, and analysis of protein oligomerization, biomolecular interactions, and macromolecular assemblies. Utilizing the novel technologies of mass photometry and macro mass photometry, Refeyn’s products are capable of accurate analysis of single particles in solution, in their native state, and without the need for labels, opening up new possibilities for bioanalytics.

Content by Refeyn

Abstract scientific concepts with A scientist pipetting in the background
| 3 min read
Page 1 of 1 - 1 Total Items
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist wearing gloves handles a pipette over a petri dish and a color-coded microplate in a laboratory setting.

The unsung tools behind analytical testing success

Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
A 3D rendering of motor neurons lit up with blue, purple, orange, and green coloring showing synapses against a black background.

Improving ALS research with pluripotent stem cell-derived models 

Discover new advancements in modeling amyotrophic lateral sclerosis.

Automating 3D cell selection

Discover precise automated tools for organoid and spheroid handling. 
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue